FDAAPP / MONTHLY
Important information: If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.
Before Jul 1, 2026
Resolves Yes if If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.
Note: this event is directional.
Contracts settle at $1.00 if the outcome resolves Yes, and $0.00 if it resolves No. Positions can be closed any time before expiration at the prevailing market price.
Contracts settle at $1.00 if the outcome resolves Yes, and $0.00 if it resolves No. Positions can be closed any time before expiration at the prevailing market price.